Floatz logo

Setmelanotide

Bardet Biedl Syndrome (BBS)

Tom Hühneprotein_peptidePhase 4 / ApprovedActive
A
81/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Bardet Biedl Syndrome (BBS) cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Setmelanotide is also rated in:

Alstrom syndromeDormant
BBB
Indicative ·
75 / 100
View asset →
inherited obesityDormant
BBB
Indicative ·
73 / 100
View asset →
obesity due to pro-opiomelanocortin deficiencyDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →